Inhibrx Announces Participation in Upcoming Scientific Conference

Rhea-AI Summary

Inhibrx (Nasdaq: INBX) will present clinical data at the ESMO Sarcoma and Rare Cancers Congress in Lugano, Switzerland, March 12-14, 2026. A mini oral session on March 12 will feature the Phase 1 study of tetravalent DR5 agonist ozekibart (INBRX-109) combined with irinotecan and temozolomide in adolescents and adults with Ewing sarcoma.

Lead author is Rashmi Chugh, M.D.; presenting author is Ana Sebio, M.D., Ph.D. The presentation (abstract 84MO) is scheduled for March 12 at 11:30 am CET in Hall A, Palazzo dei Congressi Lugano, and will be accessible via a link on the company investor website upon commencement.

News Market Reaction – INBX

-4.08%

-4.08% Session close to close

In the Mar 3 session, INBX declined 4.08%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conference:

ESMO Sarcoma and Rare Cancers Congress
March 12^th- 14^th, 2026; Lugano Switzerland

Title: Phase 1 Study of the Tetravalent Death Receptor 5 (DR5) Agonist Ozekibart (INBRX-109) Combined With Irinotecan (I) and Temozolomide (T) in Adolescents and Adults With Ewing Sarcoma
Abstract number: 84MO
Lead Author: Rashmi Chugh, M.D. (Presenting author: Ana Sebio, M.D., Ph.D.)
Format: Mini oral session 1: Sarcoma presentation
Date: Thursday, March 12^th, 2026
Time: 11:30 am CET
Location: Hall A at the Palazzo dei Congressi Lugano; Lugano, Switzerland

The presentation will be accessible through a link on the investors' section of Inhibrx's website at https://inhibrxbiosciences.investorroom.com/events-and-presentations upon commencement of the event.

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of 92% of the issued and outstanding shares of Inhibrx Biosciences. Following such transactions, Inhibrx Biosciences' current clinical pipeline of therapeutic candidates includes ozekibart and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what we believe to be the most appropriate agonist function. For more information, please visit www.inhibrx.com.

Investor and Media Contact:

Kelly Deck, CFO
ir@inhibrx.com
858-795-4260

View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-announces-participation-in-upcoming-scientific-conference-302701522.html

SOURCE Inhibrx Biosciences, Inc.

FAQ

When will Inhibrx (INBX) present at ESMO Sarcoma and Rare Cancers Congress 2026?

Inhibrx will present on Thursday, March 12, 2026 at 11:30 am CET. According to Inhibrx, the presentation is a mini oral session (abstract 84MO) in Hall A at Palazzo dei Congressi Lugano and is part of the March 12-14 conference schedule.

What will Inhibrx (INBX) present about INBRX-109 at the March 2026 conference?

Inhibrx will present Phase 1 data for ozekibart (INBRX-109) combined with irinotecan and temozolomide. According to Inhibrx, the abstract covers adolescents and adults with Ewing sarcoma and is listed as abstract number 84MO in a mini oral sarcoma session.

Who are the authors presenting Inhibrx INBRX-109 data at ESMO Sarcoma 2026?

Lead author is Rashmi Chugh, M.D., with Ana Sebio, M.D., Ph.D. as the presenting author. According to Inhibrx, Dr. Chugh is listed as lead author and Dr. Sebio will deliver the mini oral presentation in Lugano.

How can investors watch the Inhibrx (INBX) presentation at ESMO Sarcoma 2026?

Investors can access the presentation via a link on the company's investor website once the session begins. According to Inhibrx, the presentation will be made available through the investors' events and presentations page upon commencement of the event.

What is the format and location of Inhibrx's presentation at the March 12, 2026 session?

The presentation is a mini oral session in Hall A at the Palazzo dei Congressi Lugano. According to Inhibrx, the session is part of the ESMO Sarcoma and Rare Cancers Congress and is scheduled for 11:30 am CET on March 12.

Will the Inhibrx (INBX) presentation cover clinical results for Ewing sarcoma treatments?

Yes, the presentation covers Phase 1 clinical study results for ozekibart combined with irinotecan and temozolomide in Ewing sarcoma. According to Inhibrx, the abstract presents safety and preliminary data from adolescents and adults in that trial.